NCT04291937
Approved For Marketing
Not Applicable
A Multicenter Expanded Access Treatment Protocol of Lurbinectedin (PM01183) in Previously Treated Small Cell Lung Cancer in the USA
ConditionsSmall Cell Lung Cancer
DrugsLurbinectedin
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Small Cell Lung Cancer
- Sponsor
- Jazz Pharmaceuticals
- Status
- Approved For Marketing
- Last Updated
- 5 years ago
Overview
Brief Summary
This is an expanded access program in the USA to enable eligible patients with previously treated small cell lung cancer to access lurbinectedin treatment prior to FDA approval. Sites must apply to participate in the program. A medical doctor must assess whether the potential benefit outweighs the risk of the investigational therapy considering the program eligibility criteria and the individual patient's medical history.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Legally competent adult
- •Confirmed and unresectable Small Cell Lung Cancer (SCLC)
- •Patients must have received one prior chemotherapy containing line
- •Adequate organ, hematological, kidney, metabolic and liver function
- •Recovery from toxicities related to previous treatment(s)
- •Pregnancy must be excluded, medically acceptable contraception method
Exclusion Criteria
- •Prior treatment with lurbinectedin
- •Certain concomitant diseases/conditions
- •Symptomatic, steroid-requiring or progressive CNS involvement.
- •Pregnant or breast-feeding women.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Approved For Marketing
Not Applicable
Expanded Access Program (EAP): Allow Patients in the US With Idiopathic Pulmonary Fibrosis Access to PirfenidoneIdiopathic Pulmonary FibrosisNCT02141087Genentech, Inc.
Approved For Marketing
Not Applicable
BMN 110 US Expanded Access ProgramMucopolysaccharidosis IVAMorquio A SyndromeMPS IVANCT01858103BioMarin Pharmaceutical
No Longer Available
Not Applicable
A Multi-site Expanded Access Program for MDMA-assisted Psychotherapy for Patients With Treatment-resistant PTSDPost Traumatic Stress DisorderNCT04438512Lykos Therapeutics
Available
Not Applicable
Expanded Access to Ensartinib for Participants With ALK+ NSCLCNon-Small Cell Lung CancerALK Gene Rearrangement PositiveNCT04146571Xcovery Holdings, Inc.
Approved For Marketing
Not Applicable
An Open-Label, Multi-Center, Expanded Access Program With Eribulin for the Treatment of Advanced Breast Cancer RefractoryMetastatic Breast CancerNCT01240421Eisai Inc.